500 Boylston Street
54 articles with PureTech
PureTech Affiliate Vedanta Biosciences Raises Additional $16.6 Million of Series C Financing, Bringing Total Capital Raised to $62.1 Million
PureTech Health plc (LSE: PRTC) (“PureTech”), a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to note that its affiliate, Vedanta Biosciences, added $16.6 million to its Series C financing round, bringing the total capital raised to $62.1 million.
PureTech Health plc, announced that Joichi “Joi” Ito, Ph.D., has stepped down from the board of directors, and current board member, Chris Viehbacher, will act as interim chair.
Wholly owned program adds to Company’s growing internal pipeline focused on lymphatic targeting and tissue-selective immunomodulation
The asset, LYT-100, is an oral compound that has shown anti-fibrotic and anti-inflammatory properties.
PureTech Announces Issuance of U.S. Patent Covering Compositions of Matter for Immuno-Oncology Program Targeting Galectin-9
Fully human, potentially first-in-class, monoclonal antibody designed to target a fundamental immunosuppressive mechanism in hard-to-treat cancers
PureTech Establishes New Corporate Headquarters in Boston’s Seaport District to Support Expansion and Acceleration of Internal R&D Pipeline
Company will continue to leverage leadership in Brain-Immune-Gut axis biology to develop novel categories of therapeutics
PureTech Health plc. announced that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, at 11:30 AM EDT.
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
PureTech Health plc announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform
PureTech Health to receive up to $26 million in upfront payments, research support, and preclinical milestones and is eligible to potentially receive more than $200 million in milestones, in addition to royalties
PureTech, which has headquarters in Boston, but is listed in London, signed a research collaboration deal with Germany’s Boehringer Ingelheim. The companies will work to develop novel product candidates using PureTech’s proprietary lymphatic targeting technology for immune modulation.
PureTech Health Announces Presentation of Internal Immuno-Oncology Programs at American Association for Cancer Research (AACR) Annual Meeting
Internal development programs targeting Galectin-9 (LYT-200) and γδ1 T cells (LYT-210) represent novel approaches to targeting immunosuppression in cancer
Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT
PureTech Health plc, an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut Axis, announced two presentations at upcoming investor conferences.
1/29/2019The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc...
Boston-based biotech company Karuna Pharmaceuticals completed a $42 million Series A financing. The round included the issuance of $22 million in shares upon conversion of debt into equity.
PureTech Health Collaborator Publishes in Journal Nature Regarding New Insights into Key Role of Brain Lymphatics in Alzheimer’s and Other Neurodegenerative Diseases
Related intellectual property exclusively licensed to PureTech Health and being advanced as part of growing internal research and development division
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides
PureTech Health to receive up to $36 million in upfront payments, research support, and early preclinical milestones and is eligible to potentially receive over $1 billion in development milestones
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
Vedanta Biosciences announced that Chief Executive Officer, Bernat Olle, Ph.D., will present at the Jefferies 2018 Global Healthcare Conference.
PureTech Health plc announced that Joep Muijrers, Ph.D., Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference.